Morgan Stanley highlights clinical, regulatory, and launch milestones across five biotechnology companies.

Overview

Morgan Stanley summarizes management commentary from the second day of its 2026 Global Healthcare Conference for Ascendis, Pharvaris, Monopar, Atea, and Adagene. The discussion centers on clinical differentiation, regulatory timing, commercialization plans, addressable markets, cash runways, and company-specific development risks.

Core views

For Pharvaris, management framed CHAPTER-3 data as approaching injectable-like efficacy in hereditary angioedema (HAE) prophylaxis. It argued that the approximately 2.1 placebo attack rate was consistent with competitor trials, while the approximately 3.6 baseline attack rate reflected a more severe population. Safety discussion included two asymptomatic Grade 3 liver-enzyme elevations without elevated bilirubin, one Grade 4 serious adverse event of laryngeal dyskinesia attributed to frequent prior intubation, no additional cardiovascular signals, a TQT waiver, and gastrointestinal adverse-event rates balanced across study arms. Management sees a growing prophylaxis market, supported by treatment guidelines, patients who discontinued Orladeyo, 150–250 newly diagnosed patients annually, and demand from patients seeking an oral alternative to injectables. It also highlighted launch preparation for deucrictibant, including a planned field force of 35 people and roughly 90 total employees at prophylaxis launch, alongside an opt-in patient program targeted to rise from about 2,000 to 3,000 patients. Management expects the acquired-angioedema CREAATE readout in 1Q27 and intends to combine those data with the prophylaxis NDA filing. Monopar expects to complete its rolling NDA submission for ALXN1840 in Wilson disease within the next few months. Upcoming AASLD presentations on November 5–9, 2026 include Phase 3 FoCus baseline findings on residual disease burden and a poster on neutral molybdenum balance and lack of molybdenum toxicity. Management cited prior Phase 3 analyses showing significant neurologic benefit versus standard of care in patients with neurologic symptoms, and Phase 2 evidence of improved daily copper balance, stabilized liver disease, and clinically meaningful improvements in neurologic symptoms and quality of life. The company received FDA Rare Pediatric Disease designation for ALXN1840 on June 30, 2026, potentially supporting a pediatric Priority Review Voucher upon approval. It ended 2Q26 with $134.3 million of cash, cash equivalents and equivalents, which management expects to fund operations through at least December 31, 2027. Atea reported that C-BEYOND met its FDA-agreed Phase 3 SVR12 primary endpoint: the eight-week bemnifosbuvir/ruzasvir regimen was non-inferior to 12 weeks of Epclusa in non-cirrhotic HCV patients, with 94–95% cure rates and a clean safety and tolerability profile. Management expects the confirmatory C-FORWARD study, spanning more than 17 countries and including a broader genotype mix with roughly 50% genotype 3, to reproduce those results; data are expected in early 1Q27. Rather than pursuing marginally higher cure rates above the approximately 95% ceiling, the company is positioning the regimen around shorter treatment duration, lower drug-drug-interaction risk, no food effect, and no protease inhibitor. It targets an NDA filing by mid-2027 and an EMA filing at end-2027. Management cited an estimated US infected population of about 4 million, approximately 160,000 new diagnoses annually, and only about half of diagnosed patients treated; it expects a third specialty-care entrant could capture roughly 33–35% share. Atea also described hepatitis E as a longer-term opportunity and reported roughly $220 million of cash at end-June, with runway through end-2027 or early 2028. Adagene presented ADG126 as a differentiated masked anti-CTLA-4 approach: its SAFEbody mask is intended to be removed only where intratumoral protease activity and CTLA-4 expression are high, potentially improving the therapeutic index. In late-line microsatellite-stable colorectal cancer without liver metastases, ADG126 plus pembrolizumab produced response rates of 15–36% in a small dataset, compared with historical response rates of about 0% for PD-1 monotherapy and 2–3% for tremelimumab in a randomized Phase 2 study. Management cited safety data from more than 60 patients dosed up to 20 mg/kg, versus 1–3 mg/kg for ipilimumab, with adverse-event discontinuations below 10% and no Grade 4/5 events. Randomized Phase 2 data are guided for 1H27, potentially enabling FDA discussions around mid-2027 if data mature sufficiently. Management estimates an initial US market of just over 10,000 late-line non-liver-metastatic MSS-CRC patients and a global opportunity above $1 billion; collaborations with Incyte and Sanofi could broaden development settings. Cash runway to 2H28 is expected to cover the ongoing randomized Phase 2 and partly fund a future randomized Phase 3. For Ascendis, the report identifies Skytrofa, Yorvipath, and TransCon CNP as the revenue drivers in its valuation model. Potential positive factors include strong Yorvipath launch execution, Skytrofa sales ahead of expectations, undifferentiated competing pipeline data, and market acceptance of platform-expansion opportunities. Key downside considerations are a slow Yorvipath launch in the US and EU, competing TransCon pipeline data that creates market hesitation, and regulatory or intellectual-property setbacks for TransCon CNP.

Analysis framework

The report synthesizes management commentary from the conference, focusing on clinical evidence, trial design, safety, regulatory timelines, commercialization plans, market sizing, cash runway, and stated catalysts and risks. It also references company-specific discounted-cash-flow valuation frameworks for the covered equities.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Morgan Stanley derives price targets by estimating future company cash flows or risk-adjusted revenues and discounting them using company-specific discount rates and terminal growth assumptions.

• Industry AnalysisSupply-demand framework

  Patient-population and market-opportunity assessment

  The report uses patient populations, diagnosis and treatment rates, switching behavior, and physician concentration to assess commercial opportunities for HAE, HCV, and oncology programs.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Ascendis Pharma A/S (ASND)

  Covered biotechnology company; valuation is driven by Skytrofa, Yorvipath, and TransCon CNP.

  Strengths

  Potential strong Yorvipath launch, Skytrofa sales ahead of expectations, and platform-expansion opportunities.

  Comparison

  Potentially differentiated versus competing pipeline programs.

  Risks

  Slow Yorvipath launch, competitive TransCon data, and regulatory or IP setbacks for TransCon CNP.

• Pharvaris (PHVS)

  Covered HAE-focused biotechnology company developing deucrictibant.

  Strengths

  Management highlighted injectable-like efficacy potential, oral-treatment demand, and ongoing launch preparation.

  Comparison

  Management compared placebo and baseline attack rates with competitor trials and cited switching potential from icatibant and injectable therapies.

  Risks

  Breakthrough attacks may rise when moving from a two-week to a four-week treatment regimen.

• Monopar Therapeutics (MNPR)

  Covered biotechnology company developing ALXN1840 for Wilson disease.

  Strengths

  Rolling NDA progress, Rare Pediatric Disease designation, and cited neurologic and copper-balance data.

  Comparison

  Phase 3 analyses were described as showing neurologic benefit versus standard of care.

  Risks

  Disappointing ALXN1840 regulatory outcome or commercial execution.

• Atea Pharmaceuticals (AVIR)

  Covered biotechnology company developing bemnifosbuvir/ruzasvir for HCV.

  Strengths

  C-BEYOND met its endpoint with 94–95% cure rates, and management highlighted an eight-week regimen with lower DDI risk and no food effect.

  Comparison

  The regimen was non-inferior to 12 weeks of Epclusa in non-cirrhotic patients.

  Risks

  Poor clinical data, approval delays or failure, declining HCV market opportunity, and pricing pressure.

• Adagene Inc. (ADAG)

  Covered oncology biotechnology company developing ADG126.

  Strengths

  SAFEbody masking approach, encouraging small-dataset response rates, and manageable reported safety profile.

  Weaknesses

  Clinical conclusions remain dependent on forthcoming randomized data.

  Comparison

  Management compared ADG126 combination response rates with historical PD-1 monotherapy and tremelimumab data.

  Risks

  Failure to demonstrate differentiated data versus Yervoy, biomarker-strategy failure, or stronger competitor clinical profiles.

Key data

• Atea C-BEYOND cure rate94–95%SVR12 cure rates for the eight-week regimen in non-cirrhotic HCV patients.
• Atea C-FORWARD data timingEarly 1Q27Expected confirmatory Phase 3 data timing.
• Monopar cash runway$134.3M through at least December 31, 2027Cash, cash equivalents and equivalents reported at the end of 2Q26.
• Adagene ADG126 response rate15–36%Small late-line MSS-CRC dataset without liver metastases in combination with pembrolizumab.
• Adagene randomized Phase 2 data timing1H27Guided timing for ADG126 data in late-line MSS-CRC without liver metastases.
• Atea US HCV population~4M infected; ~160K new diagnoses/yearManagement estimate; only about half of diagnosed patients are treated.

Impact & implications

The report portrays value creation across the covered group as dependent on clinical readouts, regulatory progress, differentiated product profiles, and successful commercialization. Near- and medium-term milestones include Monopar’s NDA completion, Atea’s C-FORWARD data and filings, Adagene’s randomized Phase 2 data, and Pharvaris’s HAE launch and prophylaxis-development execution.

Risks

• Pharvaris faces the possibility of more breakthrough attacks with a move from two-week to four-week treatment intervals.
• Monopar could face disappointing ALXN1840 regulatory outcomes or commercial execution.
• Atea faces risks of poor BEM+RZR clinical data, delayed or absent approval, reduced HCV opportunity, and pricing pressure.
• Adagene may fail to show differentiated ADG126 data versus Yervoy, its biomarker-driven approach may fail, or competitors may produce stronger clinical profiles.
• Ascendis faces risks from a slow Yorvipath launch, competitive pipeline data, and TransCon CNP regulatory or IP setbacks.

What to watch

• Monopar’s completion of the rolling ALXN1840 NDA submission and AASLD presentations in November 2026.
• Atea’s C-FORWARD Phase 3 readout in early 1Q27 and planned NDA and EMA filing timelines.
• Adagene’s randomized Phase 2 ADG126 data in 1H27 and potential FDA registration-pathway discussion around mid-2027.
• Pharvaris’s deucrictibant launch preparations, prophylaxis filing plans, and CREAATE topline readout in 1Q27.
• Ascendis’s Yorvipath launch performance, Skytrofa sales, and TransCon CNP regulatory and competitive developments.